BCD-100 - first russian PD-1 inhibitor
- Authors: Tyulyandin SA1, Fedyanin MY.1, Semiglazova TY.2, Moiseenko VM3, Odintsova SV4, Alekseev BY.5, Ivanov RA6, Shustova MS6
-
Affiliations:
- N.N.Blokhin National Medical Cancer Research Center of the Ministry of Health of the Russian Federation
- N.N.Petrov National Medical Cancer Research Center of the Ministry of Health of the Russian Federation
- Saint Petersburg Clinical Research and Practical Center for Specialized (oncological) Care
- Limited Liability Company “BioEq”
- National Medical Research Radiological Center of the Ministry of Health of the Russian Federation
- Joint-Stock Company “BIOCAD”
- Issue: Vol 19, No 3 (2017)
- Pages: 5-12
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/27133
- ID: 27133
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
S A Tyulyandin
N.N.Blokhin National Medical Cancer Research Center of the Ministry of Health of the Russian Federationд-р мед. наук, проф., зам. дир., зав. отд-нием клинической фармакологии и химиотерапии 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
M Yu Fedyanin
N.N.Blokhin National Medical Cancer Research Center of the Ministry of Health of the Russian Federationканд. мед. наук, ст. науч. сотр. отд-ния клинической фармакологии и химиотерапии 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
T Yu Semiglazova
N.N.Petrov National Medical Cancer Research Center of the Ministry of Health of the Russian Federationд-р мед. наук, зав. отд. инновационных методов терапевтической онкологии и реабилитации, вед. науч. сотр. 197758, Russian Federation, Saint Petersburg, pos. Pesochnyi, ul. Leningradskaia, d. 68
V M Moiseenko
Saint Petersburg Clinical Research and Practical Center for Specialized (oncological) Careд-р мед. наук, проф., дир. 197758, Russian Federation, Saint Petersburg, pos. Pesochnyi, ul. Leningradskaia, d. 68 a, lit. A
S V Odintsova
Limited Liability Company “BioEq”канд. мед. наук, врач-онколог 197342, Russian Federation, Saint Petersburg, Krasnogvardeiskii per., d. 23, lit. Zh
B Ya Alekseev
National Medical Research Radiological Center of the Ministry of Health of the Russian Federationд-р мед. наук, проф., зам. дир. Института по научной работе 198515, Russian Federation, Obninsk, ul. Koroleva, d. 4
R A Ivanov
Joint-Stock Company “BIOCAD”PhD, вице-президент по разработкам и исследованиям 198515, Saint Petersburg, Petrodvortsovyi r-n, p. Strel'na, ul. Sviazi, 34, lit. A
M S Shustova
Joint-Stock Company “BIOCAD”дир. клинической разработки по направлению «Онкология» 198515, Saint Petersburg, Petrodvortsovyi r-n, p. Strel'na, ul. Sviazi, 34, lit. A
References
- World Health Organization. Cancer Fact sheet, February 2017. URL: http://www.who.int/mediacentre/factsheets/fs297/en/ Assessed: 26.09.2017.
- Li Y, Li F, Jiang F et al. A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints. Cho WC, ed. IntJ Mol Sci 2016; 17 (7): 1151.
- Hessell A.J, Hangartner L, Hunter M. et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449:101-4.
- Hezareh M, Hessell A.J, Jensen R.C. et al. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1.JVirol 2001; 75:12161-8.
- Hodi F.S, Hwu W-J, Kefford R et al. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. J Clin Oncol 2016; 34 (13): 1510-7.
- Patnaik A, Kang S.P, Rasco D. et al. Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res 2015; 21 (19): 4286-93.
- A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies (MDX1106-01). ClinicalTrials.gov Identifier: NCT00441337 https://clinicaltrials.gov/ct2/show/NCT00441337 Assessed: 09.10.2017.
- Osorio J.C, Ni A, Chaft J.E. et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 2017; 28 (3): 583-9.
- Metcalfe W, Anderson J, Trinh V.A, Hwu W.J. Anti-programmed cell death-1 (PD-1) monoclonal antibodies in treating advanced melanoma. DiscovMed2015; 19 (106): 393-401.
- Brahmer J.R, Drake C.G, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.JClin Oncol2010;28 (19):3167-75.
- Topalian S.L, Hodi F.S, Brahmer J.R. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366 (26): 2443-54.
- Berger R, Rotem-Yehudar R, Slama G et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008; 14:3044-305.
- Lee C.K, Man J, Lord S. et al. Checkpoint inhibitors in metastatic EGFR- mutated non-small cell lung cancer-a meta-analysis. J Thorac Oncol 2017; 12 (2): 403-7.